You can seek FDA approval to launch a generic drug before the expiration of ACANYA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the ACANYA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on ACANYA:-

You can seek FDA approval to launch a generic drug before the expiration of ALDARA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the ALDARA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on ALDARA:-

A supplementary protection certificate (SPC) is a type of intellectual property right granted in the European Union. It provides an extension of the term of protection for a medicinal product that has been authorized for sale in the EU, beyond the 20-year term provided by the basic patent.

The aim of SPCs is to compensate for the time taken to get regulatory approval for a new drug, and to provide an incentive for companies to invest in research and development in the field of medicinal products.

You can seek FDA approval to launch a generic drug before the expiration of APLENZIN's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the APLENZIN's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on APLENZIN:-

You can seek FDA approval to launch a generic drug before the expiration of ARAZLO's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the ARAZLO's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on ARAZLO:-

You can seek FDA approval to launch a generic drug before the expiration of BRYHALI's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the BRYHALI's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on BRYHALI:-

You can seek FDA approval to launch a generic drug before the expiration of DUOBRII's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the DUOBRII's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on DUOBRII:-

You can seek FDA approval to launch a generic drug before the expiration of JUBLIA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the JUBLIA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on JUBLIA:-

You can seek FDA approval to launch a generic drug before the expiration of LOCOID's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the LOCOID's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on LOCOID:-

You can seek FDA approval to launch a generic drug before the expiration of SOLODYN's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the SOLODYN's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on SOLODYN:-

You can seek FDA approval to launch a generic drug before the expiration of VANOS's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the VANOS's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on VANOS:-

You can seek FDA approval to launch a generic drug before the expiration of ZYCLARA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the ZYCLARA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on ZYCLARA:-